Last reviewed · How we verify

PEGZILARGINASE — Competitive Intelligence Brief

PEGZILARGINASE (PEGZILARGINASE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed arginase 1 Enzyme Live · refreshed every 30 min

Target snapshot

PEGZILARGINASE (PEGZILARGINASE). LOARGYS provides an exogenous source of human arginase 1 enzyme to reduce plasma arginine by converting it to urea and ornithine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PEGZILARGINASE TARGET PEGZILARGINASE marketed arginase 1 2023-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEGZILARGINASE — Competitive Intelligence Brief. https://druglandscape.com/ci/pegzilarginase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: